Nkarta Inc - fluxo de caixa (NASDAQ:NKTX)

Financials

Cash from operating activities -43.51 M-67.93 M-57 M-86.16 M-99.7 M-88.7 M -88.7 M Cash from investing activities -210.08 M32.53 M-184.69 M79.02 M-129.56 M100.32 M 100.32 M Cash from financing activities 329.82 M1.2 M219.01 M691 K226.08 M141 K 141 K Free cash flow -51.02 M-72.95 M-104.11 M-114.31 M-104.11 M-89.91 M -89.91 M

Notícias

Mizuho reduz preço-alvo das ações da Nkarta devido à moderação nas vendas

Stifel reitera classificação de compra para ações da Nkarta após progresso em ensaios clínicos

Presidente da Nkarta (NKTX) Nadir vende ações no valor de US$ 11.693

Nkarta CEO Hastings sells $53,915 in NKTX stock

Nkarta (NKTX) president Nadir sells $11,693 in shares

Nkarta: Pushing Deeper Into A Discount Vs. Their Holdings, For No Real Reason (NKTX)

Stifel reduz preço-alvo das ações da Nkarta para US$ 11, mantém recomendação de compra

Stifel lowers Nkarta stock price target to $11 from $12, keeps Buy rating

Nkarta to present data on B-cell depleting therapy at rheumatology meeting

Nkarta (NKTX): Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Nkarta (NASDAQ:NKTX)